Evidence map›Paper›PMID 21267642›Full record

ArticleJournal of autism and developmental disorders2011

Reliability of eye tracking and pupillometry measures in individuals with fragile X syndrome.

Faraz Farzin, Felicia Scaggs, Crystal Hervey, Elizabeth Berry-Kravis, David Hessl

2 registry-linked trialsAbstract readValidation Study
In one paragraph

Article in Journal of autism and developmental disorders, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 45 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06957054 completednot on this mapstarted 2024, after this paper: background citation

Assessment of Neural Biomarkers in Adult Subjects With Fragile X Syndrome and Typically Developing Subjects

TypeobservationalSponsorConnecta Therapeutics, S.L.Ran2024 to 2025Enrolled20ConditionsFragile X Syndrome (FXS), Neurotypical AdultsArmsAny
NCT07654114 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluation of the Safety, Tolerability, and Effectiveness of CTH120 in Adult Males With Fragile X Syndrome

TypeinterventionalSponsorConnecta Therapeutics, S.L.Ran2026 to 2027Enrolled30ConditionsFragile X Syndrome (FXS), Fragile X SyndromeArmsCTH120, CTH120 placebo hard capsules
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Autonomic Function in Fragile X Syndrome: A Systematic Review.Journal of intellectual disability research : JIDR · 2026
    Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Remote monitoring of social attention in neurogenetic syndromes and idiopathic neurodevelopmental disability.Autism research : official journal of the International Society for Autism Research · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Evidence for Three Subgroups of FemaleFrontiers in integrative neuroscience · 2021
    Article
  16. Review
  17. Article
  18. A novel eye-tracking paradigm for indexing social avoidance-related behavior in fragile X syndrome.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Faraz FarzinDepartment of Psychology, Stanford University, 450 Serra Mall, Stanford, CA 94305, USA. ffarzin@stanford.edu
Felicia Scaggs
Crystal Hervey
Elizabeth Berry-Kravis
David Hessl

Funding

UC DAVIS CLINICAL AND TRANSLATIONAL SCIENCE CENTER: BPCAUL1RR024146 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BERGLUND, LARS F · 2006 to 2011
$27.0M
Genetics and Physiology of Social Anxiety in Fragile XK23MH077554 · NIMH · UNIVERSITY OF CALIFORNIA DAVIS · PI HESSL, DAVID R · 2005 to 2009
$772k
Spatial and Temporal Visual Attention in Infants with Fragile X SyndromeF31MH083386 · NIMH · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FARZIN, FARAZ · 2008 to 2009
$56k
NCRR NIH HHS RR024146NCRR NIH HHS UL1 RR024146NIMH NIH HHS F31 MH083386NIMH NIH HHS K23 MH077554NIMH NIH HHS MH083386NIMH NIH HHS MH77554
6 · The paper itself

Abstract

Recent insight into the underlying molecular and cellular mechanisms of fragile X syndrome (FXS) has led to the proposal and development of new pharmaceutical treatment strategies, and the initiation of clinical trials aimed at correcting core symptoms of the developmental disorder. Consequently, there is an urgent and critical need for outcome measures that are valid for quantifying specific symptoms of FXS and that are consistent across time. We used eye tracking to evaluate test-retest reliability of gaze and pupillometry measures in individuals with FXS and we demonstrate that these measures are viable options for assessing treatment-specific outcomes related to a core behavioral feature of the disorder.

Indexed as

Eye MovementsPupilAdolescentAdultChildFemaleFragile X SyndromeHumansMaleMiddle AgedNeuropsychological TestsReproducibility of ResultsTreatment OutcomeYoung Adult

Identifiers

PMID21267642
PMCPMC3196645

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.